Compare Amgen, Inc. (AMGN) vs Charter Communications Inc (CHTR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Charter Communications Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Charter Communications Inc trades at $131 (market cap $16.08B). The key difference: Amgen, Inc. is far larger — about 12.2× Charter Communications Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Charter Communications Inc pays none. Which is the better fit depends on your goals.
| AMGN | CHTR | |
|---|---|---|
Market Cap | $196.12B | $16.08B |
Sector | Health | Media |
52-Week High | $388.16 | $399.61 |
52-Week Low | $271.18 | $125.54 |
Enterprise Value | $241.41B | $112.38B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Charter Communications (CHTR) trades at $130.73, down 2.69% today, with a bearish technical signal and oversold short-term RSI. The stock shows extremely low valuation multiples (P/E 3.54, P/S 0.32) against solid profitability (ROE 30.23%, net margin 9.03%), while recent news highlights potential partnerships with SpaceX and acquisition interest from Comcast. Cash flow remains positive despite high capital expenditures, though revenue growth has stagnated near $54.8B annually.
CHTR presents a deep value opportunity with significant upside to the $204.67 consensus target, but high debt ($93.21B long-term) and competitive pressures in broadband/video markets pose risks. Investor sentiment is mixed amid earnings misses, yet analyst coverage leans bullish with 47% buy ratings. The stock's trajectory hinges on operational execution and strategic developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Charter Communications Inc
Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 54 million U.S. homes and businesses, around 40% of the country. Across this footprint, Charter serves 29 million residential and 2 million commercial customer accounts under the Spectrum brand, making it the second-largest U.S. cable company behind Comcast. The firm also owns, in whole or in part, sports and news networks, including Spectrum SportsNet (long-term local rights to Los Angeles Lakers games), SportsNet LA (Los Angeles Dodgers), SportsNet New York (New York Mets), and Spectrum News NY1.
Read more on CHTR →
